Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer. [electronic resource]
Producer: 20201014Description: 1551-1563 p. digitalISSN:- 1538-7445
- Aged
- Aged, 80 and over
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Drug Synergism
- Epithelial-Mesenchymal Transition -- drug effects
- Feasibility Studies
- Female
- Flow Cytometry -- methods
- Humans
- Janus Kinase 1 -- antagonists & inhibitors
- Lung -- pathology
- Lung Neoplasms -- drug therapy
- Male
- Mice
- Middle Aged
- Nitriles
- Protein Kinase Inhibitors -- pharmacology
- Proteomics -- methods
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Pyrazoles -- pharmacology
- Pyrimidines -- pharmacology
- RNA-Seq
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Single-Cell Analysis -- methods
- Sulfonamides -- pharmacology
- Tissue Array Analysis
- Xenograft Model Antitumor Assays
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.